Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.

Keywords : ['type diabetes sustain', 'randomised placebocontrolle trial', 'inhibitor therapy', 'weekly', 'semaglutide', 'addon']
Author : B Zinman
22

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.

Keywords : ['type diabetes sustain', 'randomised placebocontrolle trial', 'inhibitor therapy', 'weekly', 'semaglutide', 'addon']
Author : B Zinman
22

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.

Keywords : ['type diabetes sustain', 'randomised placebocontrolle trial', 'inhibitor therapy', 'weekly', 'semaglutide', 'addon']
Author : B Zinman
22

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.

Keywords : ['type diabetes sustain', 'randomised placebocontrolle trial', 'inhibitor therapy', 'weekly', 'semaglutide', 'addon']
Author : B Zinman
22

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.

Keywords : ['type diabetes sustain', 'randomised placebocontrolle trial', 'inhibitor therapy', 'weekly', 'semaglutide', 'addon']
Author : B Zinman
22

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.

Keywords : ['type diabetes sustain', 'randomised placebocontrolle trial', 'inhibitor therapy', 'weekly', 'semaglutide', 'addon']
Author : B Zinman
22

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Keywords : ['doubleblind randomise placebocontrolle trial', 'type diabetes rewind', 'cardiovascular outcome', 'dulaglutide']
Author : HC Gerstein
23

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Keywords : ['doubleblind randomise placebocontrolle trial', 'type diabetes rewind', 'cardiovascular outcome', 'dulaglutide']
Author : HC Gerstein
22

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Keywords : ['doubleblind randomise placebocontrolle trial', 'type diabetes rewind', 'cardiovascular outcome', 'dulaglutide']
Author : HC Gerstein
22

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Keywords : ['doubleblind randomise placebocontrolle trial', 'type diabetes rewind', 'cardiovascular outcome', 'dulaglutide']
Author : HC Gerstein
22